Artificial Intelligence (AI) and medical technology company Echo IQ Limited (ASX:EIQ) has identified expanded use options for the AI-backed EchoSolv technology to include the identification of disease progression for the most common heart valve abnormality, Mitral Regurgitation (MR).
Development of the new MR module is now complete and the technology is being embedded into the EchoSolv platform for deployment to new and existing customers in August 2023.
The company has previously announced its intention to incorporate additional diseases into its suite of solutions, and this new module is expected to support users in better identification of chronic Mitral Regurgitation. The introduction of this module also strengthens the commercial case for EchoSolv with the technology’s expanded capability to support detection of more than one form of structural heart disease, for additional fees. EchoSolv is already in use in clinical practice for Aortic Stenosis.
Mitral Regurgitation is the most common form of heart valve disease affecting more than 2% of the US population. The number of people in the US with moderate to severe MR is expected to double by 2030. Moderate and severe MR is associated with heart failure, heart rhythm problems, frequent hospital admissions and increased risk of death.
Echo IQ has developed a novel AI-backed software tool to give EchoSolv users an indication of the severity of a patient’s chronic Mitral Regurgitation.
Accurate and timely detection of MR, and its progression, is important in order to correctly identify those patients who might benefit from mitral valve repair and replacement surgeries which have been extensively studied and have shown significant improvement in symptoms and mortality.
This innovation from Echo IQ is an important advance, designed to improve adherence to clinical practice guidelines for mitral regurgitation,” Echo IQ Chief Medical Advisor, Professor David Playford, said.
“The significant amount of data produced in an echocardiogram is distilled simply and clearly by the EchoSolv technology and provides an evidence-based output that assists us to make decisions for our patients with mitral regurgitation.”
